{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:06:52Z","timestamp":1788566812031,"version":"build-2803163510"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world data assessing the effectiveness of biologics in patients with inflammatory bowel disease (IBD) in the Middle East are not well-established. In our study, we evaluated the effectiveness of biologic therapies in achieving clinical and endoscopic outcomes in biologic-na\u00efve patients with IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A retrospective chart review was conducted at two tertiary care gastroenterology centers using electronic medical records of patients with moderate-to-severe IBD. The study period was from October 2017 to October 2023. Patients who were on infliximab, adalimumab, ustekinumab, or vedolizumab for 12 months were included in the analysis. The primary outcomes were the percentage of IBD-related hospitalizations or surgeries, achieving steroid-free remission, and endoscopic remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 422 patients were included in the study, of whom 264 (62.5%) patients had Crohn\u2019s disease (CD) and 158 (39%) had ulcerative colitis (UC). In patients with CD, endoscopic remission was attained in 51 (52%) of the patients on adalimumab, 38 (53%) of the patients on infliximab, 34 (56%) of the patients on ustekinumab, and 16 (51%) of the patients on vedolizumab. In patients with UC, endoscopic remission was attained in 40 (56%) of the patients on infliximab, 26 (61%) of the patients on adalimumab, 8 (55%) of the patients on ustekinumab, and 11 (53%) of the patients on vedolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>adalimumab, infliximab, ustekinumab, and vedolizumab were all effective in achieving clinical and endoscopic clinical outcomes in IBD in both UC and CD. The findings of this study suggest that the efficacy of biologics in a Middle Eastern population is similar to that in a Western population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1388043","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T01:09:50Z","timestamp":1729040990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Effectiveness of biologic therapies in achieving treatment targets in inflammatory bowel disease; real-world data from the Middle East (ENROLL study)"],"prefix":"10.3389","volume":"15","author":[{"given":"Mohammad","family":"Shehab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alfadhli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wrood","family":"Alostad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Marei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Alrashed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Alatab","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/00365521.2020.1726445","article-title":"Treatment patterns for biologics in ulcerative colitis and Crohn\u2019s disease: a Danish Nationwide Register Study from 2003 to 2015","volume":"55","author":"Alulis","year":"2020","journal-title":"Scand. J. Gastroenterol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/00365521.2021.1955147","article-title":"First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study","volume":"56","author":"Anisdahl","year":"2021","journal-title":"Scand. J. Gastroenterol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/apt.15921","article-title":"Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn\u2019s disease","volume":"52","author":"Bohm","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/apt.13808","article-title":"Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn\u2019s disease","volume":"44","author":"Cosnes","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s43088-023-00361-0","article-title":"A review article of inflammatory bowel disease treatment and pharmacogenomics","volume":"12","author":"Eltantawy","year":"2023","journal-title":"Beni Suef Univ. J. Basic Appl. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"B6","unstructured":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment\n            GordonH.\n            MinozziS.\n            KopylovU.\n            VerstocktB.\n            ChaparroM.\n            BuskensC.\n          10.1093\/ecco-jcc\/jjae091J. Crohns Colitis2024"},{"key":"B9","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s00535-016-1274-1","article-title":"Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-na\u00efve and non-na\u00efve patients","volume":"52","author":"Iborra","year":"2017","journal-title":"J. Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.cgh.2013.01.012","article-title":"Adalimumab and infliximab are equally effective for Crohn\u2019s disease in patients not previously treated with anti-tumor necrosis factor-\u03b1 agents","volume":"11","author":"Kestens","year":"2013","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1093\/ibd\/izy155","article-title":"Effectiveness and safety of vedolizumab in anti-TNF-na\u00efve patients with inflammatory bowel disease\u2014a multicenter retrospective European study","volume":"24","author":"Kopylov","year":"2018","journal-title":"Inflamm. Bowel Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/jcm11030829","article-title":"How to choose the biologic therapy in a bio-na\u00efve patient with inflammatory bowel disease","volume":"11","author":"Laredo","year":"2022","journal-title":"J. Clin. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Official J. Am. Coll. Gastroenterology | ACG"},{"key":"B15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/jgh.15107","article-title":"A propensity score weighted comparison of vedolizumab and adalimumab in Crohn\u2019s disease","volume":"36","author":"Macaluso","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.cgh.2021.07.038","article-title":"Comparative efficacy for infliximab vs vedolizumab in biologic naive ulcerative colitis","volume":"20","author":"Narula","year":"2022","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.14309\/ajg.0000000000001773","article-title":"An objective comparison of vedolizumab and ustekinumab effectiveness in Crohn\u2019s disease patients\u2019 failure to TNF-alpha inhibitors","volume":"117","author":"Onali","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cgh.2013.06.010","article-title":"Comparative effectiveness of infliximab and adalimumab for Crohn\u2019s disease","volume":"12","author":"Osterman","year":"2014","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Official J. Am. Coll. Gastroenterology | ACG"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.cgh.2016.11.024","article-title":"Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis: a nationwide Danish cohort study","volume":"15","author":"Singh","year":"2017","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"B25","article-title":"The global standard for diagnostic health information","year":"2022","journal-title":"Int. Classif. Dis. 11th Revis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1388043\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T01:09:53Z","timestamp":1729040993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1388043\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":25,"alternative-id":["10.3389\/fphar.2024.1388043"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1388043","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]},"article-number":"1388043"}}